Guggenheim Maintains Buy on Inventiva, Raises Price Target to $14

9/15/2026
Impact: 75
Healthcare

Guggenheim analyst Seamus Fernandez has reiterated a Buy rating on Inventiva (NASDAQ: IVA) and increased the price target from $11 to $14. This adjustment reflects a positive outlook for the company's performance in the market.

AI summary, not financial advice

Share: